EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Drosophila chemical screen reveals synergistic effect of MEK and DGKα inhibition in Ras-driven cancer

John E La Marca, Robert W Ely, Sarah T Diepstraten, Peter Burke, Gemma L Kelly, Patrick O Humbert, Helena E Richardson iD

Disease Models & Mechanisms · 2023

DOI: 10.1242/dmm.049769 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Disease Models & Mechanisms, 2023. Verfasst von John E La Marca und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry & Chemistry, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 154 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Australian Research Council, ok.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Elevated Ras signalling is highly prevalent in human cancer; however, targeting Ras-driven cancers with Ras pathway inhibitors often leads to undesirable side effects and to drug resistance. Thus, identifying compounds that synergise with Ras pathway inhibitors would enable lower doses of the Ras pathway inhibitors to be used and also decrease the acquisition of drug resistance. Here, in a specialised chemical screen using a Drosophila model of Ras-driven cancer, we have identified compounds that reduce tumour size by synergising with sub-therapeutic doses of the Ras pathway inhibitor trametinib, which targets MEK, the mitogen-activated protein kinase kinase, in this pathway. Analysis of one of the hits, ritanserin, and related compounds revealed that diacyl glycerol kinase α (DGKα, Dgk in Drosophila) was the critical target required for synergism with trametinib. Human epithelial cells harbouring the H-RAS oncogene and knockdown of the cell polarity gene SCRIB were also sensitive to treatment with trametinib and DGKα inhibitors. Mechanistically, DGKα inhibition synergises with trametinib by increasing the P38 stress-response signalling pathway in H-RASG12V SCRIBRNAi cells, which could lead to cell quiescence. Our results reveal that targeting Ras-driven human cancers with Ras pathway and DGKα inhibitors should be an effective combination drug therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsAnimalsHumansMitogen-Activated Protein Kinase KinasesDrosophilaCell Line, TumorSignal TransductionProtein Kinase Inhibitors

Stichwörter der Autor:innen

DrosophilaRasscribChemical screeningDiacyl glycerol kinase α (DGKα)Synergism

Substanzen

Mitogen-Activated Protein Kinase KinasesAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Biochemistry & Chemistry, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia.
  • Blood Cells and Blood Cancer Division, Water and Eliza Hall Institute, Melbourne, Victoria 3052, Australia.
  • Department of Medical Biology, University of Melbourne, Melbourne, Victoria 3010, Australia.
  • Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria 3002, Australia.
  • Sir Peter MacCallum Department of Oncology, Department of Biochemistry & Pharmacology, and Department of Clinical Pathology, University of Melbourne, Melbourne, Victoria 3010, Australia.
  • Sir Peter MacCallum Department of Oncology, Department of Biochemistry & Pharmacology, and Department of Anatomy & Neuroscience, University of Melbourne, Melbourne, Victoria 3010, Australia.

ORCID-Profile: Helena E Richardson

Förderung

  • National Health and Medical Research Council
  • Australian Research Council
  • ok
  • Cancer Council Victoria
  • Victorian Cancer Agency
  • Worldwide Cancer Research
  • La Trobe University
  • Leukemia and Lymphoma Society

Zitieren

APA

La Marca, J. E., Ely, R. W., Diepstraten, S. T., Burke, P., Kelly, G. L., Humbert, P. O., & Richardson, H. E. (2023). A Drosophila chemical screen reveals synergistic effect of MEK and DGKα inhibition in Ras-driven cancer. Disease Models & Mechanisms. https://doi.org/10.1242/dmm.049769

Vancouver

La Marca JE, Ely RW, Diepstraten ST, Burke P, Kelly GL, Humbert PO, et al. A Drosophila chemical screen reveals synergistic effect of MEK and DGKα inhibition in Ras-driven cancer. Disease Models & Mechanisms. 2023. doi:10.1242/dmm.049769

BibTeX
@article{LaMarca2023,
  author = {La Marca, John E and Ely, Robert W and Diepstraten, Sarah T and Burke, Peter and Kelly, Gemma L and Humbert, Patrick O and Richardson, Helena E},
  title = {A Drosophila chemical screen reveals synergistic effect of MEK and DGKα inhibition in Ras-driven cancer},
  journal = {Disease Models & Mechanisms},
  year = {2023},
  doi = {10.1242/dmm.049769}
}
Kostenlos starten →